Abstract
The lung represents an important target for gene therapy: for correction of genetic abnormalities such as cystic fibrosis, for lung cancer therapy, and for vaccination. Genes in the form of expression plasmids can be delivered both by the intravenous route and via the airways. So-called “naked” DNA can be delivered by both of these methods, but gene expression is low. Successful delivery is usually accomplished by complexing the DNA with cationic lipids or with polycations. This review will discuss the efficacy of delivery for particular purposes by various methods and complexing agents, as well as issues of biodistribution, inflammatory reactions, and improvements in formulations. Non-viral gene delivery to the lung has a long history of development, and it is now poised to represent a significant addition to the medical arsenal.
Keywords: inflammatory diseases, gene therapy, immunization, plasmid dna, lipoplexes, expression
Current Gene Therapy
Title: Non-Viral Gene Delivery to the Lungs
Volume: 5 Issue: 2
Author(s): Berma M. Kinsey, Charles L. Densmore and Frank M. Orson
Affiliation:
Keywords: inflammatory diseases, gene therapy, immunization, plasmid dna, lipoplexes, expression
Abstract: The lung represents an important target for gene therapy: for correction of genetic abnormalities such as cystic fibrosis, for lung cancer therapy, and for vaccination. Genes in the form of expression plasmids can be delivered both by the intravenous route and via the airways. So-called “naked” DNA can be delivered by both of these methods, but gene expression is low. Successful delivery is usually accomplished by complexing the DNA with cationic lipids or with polycations. This review will discuss the efficacy of delivery for particular purposes by various methods and complexing agents, as well as issues of biodistribution, inflammatory reactions, and improvements in formulations. Non-viral gene delivery to the lung has a long history of development, and it is now poised to represent a significant addition to the medical arsenal.
Export Options
About this article
Cite this article as:
Kinsey M. Berma, Densmore L. Charles and Orson M. Frank, Non-Viral Gene Delivery to the Lungs, Current Gene Therapy 2005; 5 (2) . https://dx.doi.org/10.2174/1566523053544254
DOI https://dx.doi.org/10.2174/1566523053544254 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthetic Lethality and PARP-Inhibitors in Oral and Head & Neck Cancer
Current Pharmaceutical Design Depsipeptides from Microorganisms: A New Class of Antimalarials
Mini-Reviews in Medicinal Chemistry Novel Epigenetic Targets in Lymphoproliferative Disorders
Current Cancer Drug Targets Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design γ δ T Cell Modulation in Anticancer Treatment
Current Cancer Drug Targets Targeting Cancer Stem Cells and Non-Stem Cancer Cells: The Potential of Lipid- Based Nanoparticles
Current Pharmaceutical Design Cross-Talk between Tumor Cells and the Microenvironment at the Metastatic Niche
Current Pharmaceutical Biotechnology Emerging Insights in the Role of Tissue Factor in Cancer
Current Genomics Coagulation and Cancer Therapy: The Potential of Natural Compounds
Current Genomics Exploring and Exploiting Biologically Relevant Chemical Space
Current Drug Targets Versatile Use of Nanosponge in the Pharmaceutical Arena: A Mini-Review
Recent Patents on Nanotechnology Aminopeptidases of Malaria Parasites: New Targets for Chemotherapy
Infectious Disorders - Drug Targets Role of the Hypoxic Microenvironment in the Antitumor Activity of Tyrosine Kinase Inhibitors
Current Medicinal Chemistry Potential Clinical Applications of Multi-functional Milk Proteins and Peptides in Cancer Management
Current Medicinal Chemistry Recent Advances in Validating MDM2 as a Cancer Target
Anti-Cancer Agents in Medicinal Chemistry Glioma Stem Cell Maintenance: The Role of the Microenvironment
Current Pharmaceutical Design LncRNA HOTAIR Polymorphisms Association with Cancer Susceptibility in Different Tumor Types
Current Drug Targets Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Current Medicinal Chemistry The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies
Anti-Cancer Agents in Medicinal Chemistry The Optimal Diagnosis of Urothelial Carcinoma of the Bladder
Current Cancer Therapy Reviews